Baxter Healthcare gets European clearance for Kiovig

The European Medicines Agency (EMEA) has issued marketing authorization for Baxter Healthcare’s Kiovig.

Kiovig, the intravenous immunoglobulin (IVIG), can now be used for replacement therapy in primary immunodeficiency disorders (PID), myeloma or chronic lymphocytic leukaemia and a number of other cases including for children with congenital AIDS and recurrent infections.

Baxter Europe president Jim Utts said: “The launch of Kiovig is the latest step in Baxter’s efforts toward advancing the science of IVIG.

“We are excited to offer this new liquid IVIG to help meet the needs of physicians, healthcare professionals and patients.”

Baxter, with the approval from EMEA, will be allowed to market the therapy in all 25 European Union member states, along with Norway and Iceland.

© Adfero Ltd